Literature DB >> 27167703

Receptor activator of nuclear factor kappa-B ligand (RANKL)/RANK signaling promotes cancer-related inflammation through M2 macrophages.

Taku Fujimura1, Yumi Kambayashi1, Sadanori Furudate1, Aya Kakizaki1, Takanori Hidaka1, Masayuki Asano1, Setsuya Aiba1.   

Abstract

Entities:  

Keywords:  M2 macrophages; RANKL/RANK; extramammary Paget's disease; tolerance

Mesh：

Substances：

Year:  2016        PMID： 27167703     DOI： 10.1111/exd.12949

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN： 0906-6705            Impact factor:   3.960


× No keyword cloud information.
  4 in total

1.  RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity.

Authors:  Hong Wang; Reading Ashton; Jonathan A Hensel; Joo Hyoung Lee; Vinayak Khattar; Yong Wang; Jessy S Deshane; Selvarangan Ponnazhagan
Journal:  Mol Cancer Ther       Date:  2020-11-16       Impact factor: 6.261

2.  Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab.

Authors:  Sadanori Furudate; Taku Fujimura; Akira Tsukada; Yota Sato; Takanori Hidaka; Kayo Tanita; Yumi Kambayashi; Takahiro Haga; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2017-01-16

3.  RANKL-Expressing Ectopic Extramammary Paget's Disease on the Lower Abdomen.

Authors:  Akiko Hagiwara-Takita; Taku Fujimura; Aya Kakizaki; Setsuya Aiba
Journal:  Case Rep Dermatol       Date:  2016-06-06

Review 4.  Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer.

Authors:  Taku Fujimura; Yumi Kambayashi; Yasuhiro Fujisawa; Takanori Hidaka; Setsuya Aiba
Journal:  Front Oncol       Date:  2018-01-23       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.